Enabling global analysis of protein expression by next generation sequencing

Enabling global analysis of protein expression by next generation sequencing

06-07-2017 12:30 pm - 06-07-2017 1:30 pm
2nd Floor Community Center
953 Indiana Street, San Francisco, CA 94107

RSVP

Amgen Innovator Series

Luciano Brocchieri, PhD
Co-Founder, TB-SEQ

TB-SEQ, Inc., promotes implementations and development of the RIBO-seq platform technology, by which protein expression can be monitored and discovered with high coverage and resolution by deep-sequencing the ‘translatome’, i.e., the genome-wide pool of translated mRNAs. Selective translational control of gene expression is emerging as a widespread mechanism for the regulation of functional activities of biological systems. RIBO-seq has enabled discovery of key regulatory components and mechanisms of post-transcriptional control of translation, uncovering new functionalities and targets for intervention.

About Luciano Brocchieri
Luciano Brocchieri, PhD, Co-Founder of TB-SEQ, was formerly a Senior Scientist at Stanford University, Dept. of Mathematics, and a faculty member at the University of Florida, Department of Molecular Genetics and Microbiology. Luciano has a background in theoretical population genetics, bioinformatics, and molecular evolution. He is the author of extensive work on properties and evolution of protein families and nucleic acid sequences and has developed new methods for gene identification and for the analysis of sequencing data. Luciano is also Editor-in-Chief of the Journal of Phylogenetics and Evolutionary Biology. Along with TB-SEQ Co-founder Silvia Tornaletti, a Stanford-educated biochemist and former faculty member at the University of Florida, have previously collaborated on the analysis of translation in the bacterial pathogen Pseudomonas aeruginosa and in aging muscle.

Related upcoming events

  • 10-19-2017 12:30 pm - 10-19-2017 1:30 pm

    Daniel Laser, PhD
    CEO and Co-Founder, Applaud Medical

    RSVP

    Applaud Medical is a three-year-old company developing treatments for biomineralization-related diseases. Applaud's products use violent physical effects like cavitation and shock waves to achieve a therapeutic effect, while sparing non-targeted tissue through precise chemical targeting. Applaud's lead product, for low-invasiveness treatment of kidney stones, is currently in clinical trials in Gujarat, India. This seminar will cover technical aspects of combining chemical reactions with mechanical action in both Applaud's products and in a range of other drugs and devices, along with a brief discussion of key commercialization considerations for this uniquely promising product category.

    About Daniel Laser

    Daniel Laser is Chief Executive Officer and co-founder of Applaud Medical. Dan also founded Wave 80 Biosciences, a pioneer in detecting HIV during the high-transmission-risk earliest phase of infection, when the immune response is insufficiently advanced for antibody-based methods. He has served as board member or advisor to drug and device companies in fields ranging from autoimmune disease to ophthalmology to cancer. Dan got his start in the medical device field working on haptic feedback for telerobotic surgery systems. Dan holds a Ph.D. in mechanical engineering from Stanford University, where he was a Semiconductor Research Corporation Graduate Fellow. While at Stanford, he was also a MacArthur Affiliate at Stanford’s Center for International Security and Cooperation, developing mathematical models for protecting against threats involving weaponized pathogens.

  • 11-01-2017 12:30 pm - 11-01-2017 1:30 pm

    Michael R. Harrison, MD
    Founder, MAGNAP
    Professor of Surgery, Pediatrics, OB-GYN, and Reproductive Sciences, Emeritus
    University of California, San Francisco

    RSVP

    Patients with Obstructive Sleep Apnea (OSA) can have their airway opened by pulling the hyoid bone and all its attachments to the airway anteriorly. But how? We have developed and are now testing in a first-in-human trial the Magnap System. A titanium encased magnet is implanted on the hyoid in an outpatient procedure. When going to sleep the patient puts on a separate external brace containing a second magnet, the airway is held open and OSA resolved.

    About Dr. Michael Harrison
    Dr. Michael Harrison is Professor of Surgery, Pediatrics, and Obstetrics, Gynecology and Reproductive Sciences, Emeritus, a position he assumed in 2006 after a long-distinguished academic pediatric surgery career at UCSF beginning in 1978.  He is also the Founding Director of the UCSF Fetal Treatment Center. Dr. Harrison earned his B.A. degree from Yale University and his M.D. degree from Harvard Medical School. He completed pediatric surgery fellowship at the Rikshospitalet in Oslo, Norway, and at the Children’s Hospital of Los Angeles. Dr. Harrison joined the Department of Surgery at UCSF in 1978, with joint appointments in pediatrics and obstetrics, gynecology and reproductive sciences. There are currently efforts underway to establish a distinguished professorship in his honor.

    Dr. Harrison is a member of numerous scientific societies, serves on the editorial boards, and has served on several national committees including the Committee on the Status of the Anencephalic as Donor (1994-99). As a member of various medical and surgical professional societies, he has been recognized by his colleagues for his contributions to the field and honored with a number of prestigious awards, including the American College of Surgeons’ Jacobson Innovation Award and Sheen Award, the First Professor P.P. Rickman Award of the British Association of Paediatric Surgeons, the Golden Plate Award of the American Academy of Achievement, the Arnold M. Salzberg Mentorship Award of the American Academy of Pediatrics, the Michaël Vloten Award of the Congress of the Association of Surgeons of the Netherlands, and induction into the Institute of Medicine

Upcoming Event

  • Reaction before action: new approaches to biomineralization-associated diseases

    12:30-13:30
    10/19/2017
    Daniel Laser, PhD CEO and Co-Founder, Applaud Medical RSVP Applaud Medical is a three-year-old company developing treatments for biomineralization-related diseases. Applaud's products use violent physical effects like cavitation and shock waves to achieve a therapeutic effect, while sparing non-targeted tissue through precise chemical targeting. Applaud's lead product, for low-invasiveness treatment of kidney stones, is currently in clinical trials in Gujarat, India. This seminar will cover technical aspects of combining chemical reactions with mechanical action in both Applaud's products and in a range of other drugs and devices, along with a brief discussion of key commercialization considerations for this uniquely promising product category. About Daniel Laser Daniel Laser is Chief Executive Officer and co-founder of Applaud Medical. Dan also founded Wave 80 Biosciences, a pioneer in detecting HIV during the high-transmission-risk earliest phase of infection, when the immune response is insufficiently advanced for antibody-based methods. He has served as board member or advisor to drug and device companies in fields ranging from autoimmune disease to ophthalmology to cancer. Dan got his start in the medical device field working on haptic feedback for telerobotic surgery systems. Dan holds a Ph.D. in mechanical engineering from Stanford University, where he was a Semiconductor Research Corporation Graduate Fellow. While at Stanford, he was also a MacArthur Affiliate at Stanford’s Center for International Security and Cooperation, developing mathematical models for protecting against threats involving weaponized pathogens.

Address

953 Indiana St., San Francisco, CA 94107
Tel: (415)-347-8287
Map

Sign-Up for our Newsletter